Jae Kyung Roh

TL;DR: In this paper, the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer was investigated.

TL;DR: Addition of cetuximab to platinum-based chemotherapy represents a new treatment option for patients with advanced non-small-cell lung cancer.

TL;DR: Treatment with radiation alone had suboptimal results, partly because of the occurrence of a variety of systemic failure with diverse clinicopathologic features, and it is believed that the multimodality treatment approach containing more effective chemotherapeutic agents should be incorporated in the treatment of angiocentric lymphoma confined to the head and neck.

TL;DR: The FLEX study as discussed by the authors showed that the addition of cetuximab to cisplatin and vinorelbine significantly improved overall survival in the first-line treatment of EGFRexpressing, advanced non-small-cell lung cancer (NSCLC).

TL;DR: Epigenetic therapy with belinostat demonstrates tumor stabilization and is generally well-tolerated and HR23B expression was associated with disease stabilization.